The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It

A paid market commentary article highlights the growing trend of treating facial volume loss caused by GLP-1 weight-loss drugs, citing AbbVie's Allergan Aesthetics division as a key large-cap anchor in the space. The article notes that AbbVie's medical-affairs leadership is actively co-authoring clinical literature on treating GLP-1 aesthetic patients, validating the market opportunity alongside peers like Galderma, Establishment Labs, and InMode.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.